Prolactinoma in postmenopausal women: a systematic review.

Prolactinomas occurring during the reproductive period exhibit a characteristic behavior. There are, however, gaps in the literature regarding the behavior of these tumors after menopause. This study aimed to review and characterize the influence of menopause on prolactinoma behavior. A systematic review of observational prospective or retrospective studies and clinical trials on prolactinomas was conducted in two situations: tumors diagnosed in the reproductive period (before menopause), with follow-up in the postmenopausal period, or prolactinomas diagnosed in the postmenopausal period, without language or date restrictions. Data extracted from the articles included patient and tumor characteristics (prolactinoma type, previous treatment, symptoms, and serum prolactin [PRL] levels). This study included five studies comprising 180 participants. Prolactinomas diagnosed in women of reproductive age are treated with dopaminergic agonists (DAs), with indications of treatment withdrawal after menopause, exhibited stable tumor behavior and PRL levels. Considering the diagnosis during the postmenopausal period, macroprolactinomas were more prevalent and showed tumor shrinkage when DAs were used. Cabergoline, the most commonly used drug, lowers PRL levels and reduces symptoms associated with adenoma. Microadenomas diagnosed before menopause can be followed up without treatment. Prolactinomas diagnosed after menopause are typically macroadenomas. Cabergoline remains the treatment of choice in the presence of clinical or compressive symptoms. We recommend at least one annual follow-up for such patients. Copyright © 2024 by The Menopause Society.

Citation

Marcela Souza Carneiro, Ticiana Aparecida Alves de Mira, Daniela Angerame Yela, Cristina Laguna Benetti-Pinto. Prolactinoma in postmenopausal women: a systematic review. Menopause (New York, N.Y.). 2024 Feb 01;31(2):160-167

Mesh Tags

Substances

PMID: 38194617

search → result